Display options
Cite
Zheng D, Wang R, Zhang Y, et al. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. Onco Targets Ther. 2016;9:833-43doi: 10.2147/OTT.S96834.
Zheng, D., Wang, R., Zhang, Y., Pan, Y., Cheng, X., Cheng, C., Zheng, S., Li, H., Gong, R., Li, Y., Shen, X., Sun, Y., & Chen, H. (2016). The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. OncoTargets and therapy, 9833-43. https://doi.org/10.2147/OTT.S96834
Zheng, Difan, et al. "The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations." OncoTargets and therapy vol. 9 (2016): 833-43. doi: https://doi.org/10.2147/OTT.S96834
Zheng D, Wang R, Zhang Y, Pan Y, Cheng X, Cheng C, Zheng S, Li H, Gong R, Li Y, Shen X, Sun Y, Chen H. The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations. Onco Targets Ther. 2016 Feb 22;9:833-43. doi: 10.2147/OTT.S96834. eCollection 2016. PMID: 26955281; PMCID: PMC4768896.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 Feb 22;9:833-43. doi: 10.2147/OTT.S96834. eCollection 2016.

The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations.

OncoTargets and therapy

Difan Zheng, Rui Wang, Yang Zhang, Yunjian Pan, Xinghua Cheng, Chao Cheng, Shanbo Zheng, Hang Li, Ranxia Gong, Yuan Li, Xuxia Shen, Yihua Sun, Haiquan Chen

Affiliations

  1. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
  2. Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
  3. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
  4. Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China; Institutes of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China.

PMID: 26955281 PMCID: PMC4768896 DOI: 10.2147/OTT.S96834

Abstract

BACKGROUND: We performed this retrospective study to identify the prevalence of KRAS mutation in Chinese populations and make a comprehensive investigation of the clinicopathological features of KRAS mutation in these patients.

PATIENTS AND METHODS: Patients from 2007 to 2013 diagnosed with primary lung adeno-carcinoma who received a radical resection were examined for KRAS, EGFR, HER2, BRAF mutations, and ALK, RET, and ROS1 fusions. Clinicopathological features, including sex, age, tumor-lymph node-metastasis stage, tumor differentiation, smoking status, histological subtypes, and survival information were analyzed.

RESULT: KRAS mutation was detected in 113 of 1,368 patients. Nine different subtypes of KRAS mutation were identified in codon 12, codon 13, and codon 61. KRAS mutation was more frequently found in male patients and former/current smoker patients. Tumors with KRAS mutation had poorer differentiation. Invasive mucinous adenocarcinoma predominant and solid predominant subtypes were more frequent in KRAS mutant patients. No statistical significance was found in relapse-free survival or overall survival between patients with KRAS mutation and patients with other mutations.

CONCLUSION: In Chinese populations, we identified KRAS mutation in 8.3% (113/1,368) of the patients with lung adenocarcinoma. KRAS mutation defines a molecular subset of lung adenocarcinoma with unique clinicopathological features.

Keywords: KRAS; NSCLC; prognosis; surgery

References

  1. J Thorac Oncol. 2015 May;10(5):838-43 - PubMed
  2. Clin Cancer Res. 2008 Jun 15;14(12):3867-74 - PubMed
  3. Lancet Oncol. 2008 Oct;9(10):962-72 - PubMed
  4. Carcinogenesis. 1993 Nov;14 (11):2419-22 - PubMed
  5. Lung Cancer. 2014 May;84(2):121-6 - PubMed
  6. N Engl J Med. 2010 Jun 24;362(25):2380-8 - PubMed
  7. N Engl J Med. 2014 Dec 4;371(23):2167-77 - PubMed
  8. Clin Cancer Res. 2014 Aug 1;20(15):4107-14 - PubMed
  9. Asian Pac J Cancer Prev. 2015;16(10):4439-45 - PubMed
  10. J Natl Compr Canc Netw. 2015 May;13(5):515-24 - PubMed
  11. Oncogene. 2007 May 14;26(22):3291-310 - PubMed
  12. J Natl Cancer Inst. 2012 Feb 8;104(3):228-39 - PubMed
  13. N Engl J Med. 2005 Jul 14;353(2):133-44 - PubMed
  14. Clin Cancer Res. 2008 Sep 15;14 (18):5731-4 - PubMed
  15. Lancet Oncol. 2013 Jan;14 (1):38-47 - PubMed
  16. J Clin Oncol. 2008 Mar 20;26(9):1472-8 - PubMed
  17. N Engl J Med. 2014 Oct 30;371(18):1725-35 - PubMed
  18. Cancer Lett. 2015 Mar 1;358(1):85-91 - PubMed
  19. J Thorac Oncol. 2015 Mar;10(3):431-7 - PubMed
  20. Chem Res Toxicol. 1998 Jun;11(6):559-603 - PubMed
  21. Ann Oncol. 2011 Jan;22(1):235-7 - PubMed
  22. J Clin Oncol. 2010 Nov 1;28(31):4769-77 - PubMed
  23. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  24. Clin Cancer Res. 2012 Nov 15;18(22):6169-77 - PubMed
  25. Lung Cancer. 2010 Sep;69(3):272-8 - PubMed
  26. N Engl J Med. 2013 Jun 20;368(25):2385-94 - PubMed
  27. Exp Lung Res. 1998 Jul-Aug;24(4):395-405 - PubMed
  28. J Clin Oncol. 2010 Oct 20;28(30):4616-20 - PubMed
  29. J Clin Oncol. 2013 Mar 10;31(8):1112-21 - PubMed
  30. Clin Cancer Res. 2012 Sep 1;18(17 ):4725-32 - PubMed
  31. Nature. 2013 Nov 28;503(7477):548-51 - PubMed
  32. PLoS Med. 2005 Jan;2(1):e17 - PubMed
  33. Clin Cancer Res. 1996 Feb;2(2):411-8 - PubMed
  34. N Engl J Med. 1990 Aug 30;323(9):561-5 - PubMed
  35. Cancer Discov. 2015 Aug;5(8):860-77 - PubMed
  36. Clin Cancer Res. 2006 Apr 15;12 (8):2538-44 - PubMed

Publication Types